Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

European Research Council grant · Finished

AIDA AIDA: Allergy Immunotherapy based on Designed Allergens

Coordinator
Danmarks Tekniske Universitet, Denmark
Runs
1 April 2023 to 30 September 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101112851

What the project is doing

In the project's own words, from its summary on CORDIS.

Allergy is a severe immune reaction to foreign substances known as allergens, with respiratory and food allergies affecting 30% and 10% of the global population, respectively. A high structural similarity exists between pollen and food allergens. Therefore, many people suffer from both types of allergies. Untreated allergies have detrimental effects on health-related quality of life, family economics, and work attendance.

Allergy is treated as a chronic disease, with a focus on reducing symptoms (e.g., antihistamines), which is cumbersome and expensive. The only existing curative treatment, allergen immunotherapy (AIT), consists of up to 5 years of monthly exposure to low amounts of the triggering allergen until the immune system is desensitized. Unfortunately, this approach is costly for healthcare providers and its efficacy varies, being especially low for patients allergic to multiple pollen and foodstuff sources.

Only 40% of patients choose to undergo AIT, and 20% of these terminate the treatment early due to strong side effects or lack of efficacy. We propose the development of an urgently needed AIT by treating several allergies at once, achieving tolerance faster, and reducing side effects.

Topics

Who is involved

OrganisationCityCountryRole
Danmarks Tekniske UniversitetKongens LyngbyDenmarkCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI